Literature DB >> 27885306

Impact of a National Cancer Prevention and Treatment Program on the Prevalence of Late-Stage Breast Cancer Diagnoses in Oklahoma.

Amanda Janitz1, Aaron M Wendelboe1, Ann F Chou2, Summer Frank3, Angela Watkins4, David Thompson1, Janis Campbell5.   

Abstract

In 2000, Congress passed the Breast and Cervical Cancer Prevention and Treatment Act (BCCPTA) to provide coverage through Medicaid to women who screened positive for breast and cervical cancer. We aimed to determine if late-stage breast cancer prevalence decreased among Oklahoma women after passage of BCCPTA. Data were obtained from the Oklahoma Central Cancer Registry during 2000-2011. We estimated prevalence proportion ratios (PPR) using modified Poisson regression between the proportion of women with late-stage breast cancer and timing of diagnosis related to BCCPTA. Among uninsured women, the probability of being diagnosed with late-stage cancer after enactment of the BCCPTA was 0.80 (95% CI: 0.67, 0.96) times the probability before enactment. This was significant among uninsured women living in metro counties (PPR: 0.74, 95% CI: 0.61, 0.90) but not in non-metro counties (PPR: 1.05, 95% CI: 0.71, 1.56). These findings may be similar to other rural states with large uninsured populations.

Entities:  

Mesh:

Year:  2016        PMID: 27885306      PMCID: PMC5119628     

Source DB:  PubMed          Journal:  J Okla State Med Assoc        ISSN: 0030-1876


  22 in total

1.  Comparison of breast and cervical cancer screening utilization among rural and urban Hispanic and American Indian women in the Southwestern United States.

Authors:  Tomas Nuño; Joe K Gerald; Robin Harris; Maria Elena Martinez; Antonio Estrada; Francisco García
Journal:  Cancer Causes Control       Date:  2012-06-19       Impact factor: 2.506

Review 2.  Epidemiology, stage at diagnosis, and tumor biology of breast carcinoma in multiracial and multiethnic populations.

Authors:  C P Hunter
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

3.  Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis.

Authors:  Kathleen A Cronin; Eric J Feuer; Lauren D Clarke; Sylvia K Plevritis
Journal:  J Natl Cancer Inst Monogr       Date:  2006

4.  Reduced mortality for women with mammography-detected breast cancer in east Denmark and south Sweden.

Authors:  L H Christensen; G Engholm; R Cortes; J Ceberg; U Tange; M Andersson; A Bladström; H T Mouridsen; T Möller; Hans Storm
Journal:  Eur J Cancer       Date:  2006-09-20       Impact factor: 9.162

5.  Self-reported mammography screening among Oklahoma women age 50 and older: Oklahoma Behavioral Risk Factor Surveillance System 1997-2001.

Authors:  Janis Campbell; Zoran Bursac; Adeline Yerkes; Peng Li; Kelly Baker
Journal:  J Okla State Med Assoc       Date:  2002-10

Review 6.  Determinants of cancer disparities: barriers to cancer screening, diagnosis, and treatment.

Authors:  Harold P Freeman; Kenneth C Chu
Journal:  Surg Oncol Clin N Am       Date:  2005-10       Impact factor: 3.495

7.  Impact of geography on mammography use in California.

Authors:  Monica C Jackson; William W Davis; William Waldron; Timothy S McNeel; Ruth Pfeiffer; Nancy Breen
Journal:  Cancer Causes Control       Date:  2009-05-17       Impact factor: 2.506

8.  Late stage cancers in a Medicaid-insured population.

Authors:  Cathy J Bradley; Charles W Given; Caralee Roberts
Journal:  Med Care       Date:  2003-06       Impact factor: 2.983

9.  Rural - urban inequalities in late-stage breast cancer: spatial and social dimensions of risk and access.

Authors:  Sara McLafferty; Fahui Wang; Lan Luo; Jared Butler
Journal:  Environ Plann B Plann Des       Date:  2011-08

10.  State implementation of the Breast and Cervical Cancer Prevention and Treatment Act of 2000: a collaborative effort among government agencies.

Authors:  Cynthia French; Susan True; Rosemarie McIntyre; Margherita Sciulli; Kathleen A Maloy
Journal:  Public Health Rep       Date:  2004 May-Jun       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.